The common H202D variant in GDF-15 does not affect its bioactivity but can significantly interfere with measurement of its circulating levels

3

Karusheva Y^{1,2}, Ratcliff M³, Melvin A^{1,2}, Mörseburg A^{1,2}, Sattar N⁴, Barker P^{5,2}, Burling K^{5,2}, Backmark A⁶, Roth R⁶, Jeremias L⁷, Guiu-Jurado E⁸, Blüher M⁸, Welsh P⁴, Hyvönen M³, O’Rahilly S^{*1,2}

7

¹MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

²NIHR Cambridge Biomedical Research Centre, Cambridge, UK.

³Department of Biochemistry, University of Cambridge, CB2 1GA, Cambridge, UK.

⁴British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G12 8TA, UK.

⁵Core Biochemical Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, United Kingdom.

⁶Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

⁷Cardiovascular, Renal & Metabolism, Research & Early Development, BioPharma R&D, AstraZeneca, Cambridge, UK

⁸Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.

*Correspondence to so104@medschl.cam.ac.uk.

23

24

25

26 Abstract

27 Genetic variants in proteins can interfere with measurement of their circulating concentrations. Given
 28 the growing biomedical importance of GDF-15, we wished to establish whether a common histidine
 29 to aspartate variant present in position 6 of the mature GDF-15 protein (H202D variant) interfered
 30 with its measurement by two commonly used immunoassays. We first examined the detectability of
 31 recombinant monomers, homodimers and heterodimers of GDF-15 by assays and/or reagents used in
 32 two widely used immunoassays (Roche Elecsys® GDF-15 and the R&D antibody combinations used
 33 in their Quantikine® and DuoSet® ELISA's). The Roche assay detected the H and D containing
 34 peptides similarly but the assays based on the R&D reagents consistently underreported
 35 concentrations of the D-containing variant peptide. Measurements of plasma concentrations of GDF-
 36 15 in genotyped human participants showed that the R&D reagents reported values in heterozygotes
 37 were ~25% lower, and in homozygotes, 50% lower than the Roche assay. We finally studied the
 38 activation of the GDF-15 receptor, GFRAL-Ret, in a cell based assay and found that the activities of
 39 the HH and DD containing GDF-15 peptide were indistinguishable. These results have implications
 40 for the interpretation of genetic epidemiological studies which have used the R&D reagents to
 41 measure GDF-15, and for the emerging clinical use of GDF-15 as a diagnostic and prognostic
 42 biomarker. We provide correction equations, which may be of utility for the analysis of data generated
 43 with the R&D reagents where the genotype of the participants is known.

44

45 Background

46 Growth-differentiation factor 15 (GDF-15) is a member of the transforming growth factor β (TGF- β)
 47 cytokine superfamily. Its circulating concentrations in man are elevated in a wide range of diseases
 48 such as cachexia¹, chemotherapy-related nausea² and vomiting, and hyperemesis gravidarum (HG)³.
 49 It is also elevated in mitochondrial disorders⁴⁻⁶, where it may have some diagnostic utility, and its
 50 levels are being investigated for potential prognostic value in some cancers and in heart failure^{7,8}.
 51 GDF-15 has recently gained further scientific and translational prominence with the discovery that its
 52 receptor is a GFRAL-RET heterodimer, which is found solely in the hindbrain⁹⁻¹². Activation of this

receptor results in a reduction of food intake and body weight in several animal models ¹³. These findings have prompted exploration of GFRAL-Ret agonists as potential therapy for obesity and antagonists of GDF-15 or GFRAL in various forms of cachexia. While studies in rodents and primates have consistently demonstrated the weight loss effects of GDF-15, a recent Mendelian randomisation study did not support the idea that increased levels of GDF-15 (measured by immunoassay using the R&D antibodies¹⁴) reduced human BMI. Conversely, it was suggested that genetically determined increases in circulating GDF-15 might actually predispose to obesity. As there is a common coding variant in GDF-15, which changes residue 202 from histidine to aspartic acid ^{15,16} and is present in all human populations studied to date with a minor allele frequency ranging from 14% to 35% ¹⁷, we speculated that the discrepancy between pharmacological and Mendelian randomisation studies might be due to systematic bias in the measurement of GDF-15 by certain immunoassays. To test that hypothesis, we first examined the ability of the antibody combinations from two widely used assays for human GDF-15 to detect the H and D isoforms, using the relevant synthetic homodimers and heterodimers. Secondly, we studied human plasma samples from participants of known genotype. Finally, we undertook studies comparing the functional properties of the H and D forms of GDF-15 as activators of signalling through GFRAL-Ret.

Methods

Study participants

Circulating GDF-15 concentrations were measured in plasma from 173 participants (126 women, 47 men with BMI range: 27.5-70 kg/m², age range: 21-74 years) from the Leipzig Obesity Biobank whose genotype at rs1058587 in the GDF-15 gene had previously been established from RNA sequencing data using adipose tissue obtained at surgery. Participants were randomly selected from the Biobank to represent an equal distribution of the genotype at rs1058587 ¹⁸. Plasma samples were collected in the context of elective laparoscopic abdominal surgeries as described previously ¹⁹. After extraction, plasma was immediately frozen in liquid nitrogen and stored at -80 °C. The study was approved by the Ethics Committee of the University of Leipzig (approval no: 159-12-21052012), and

performed in accordance to the declaration of Helsinki. All subjects gave written informed consent before taking part in this study. Measurement of body composition and metabolic parameters was performed as described previously^{18,19}.

Protein production

DNA encoding for mature GDF-15 was cloned into pBAT4 vector using *NcoI* and *HindIII* restriction sites, with the addition of a codon for an initiation methionine. The H202D mutation (histidine to aspartate variant present in position 6 of the mature GDF-15 protein) was introduced by PCR mutagenesis of the wild type construct. The mature GDF-15 proteins were expressed in *E. coli* in 2xYT medium at 37 °C, with all the protein forming insoluble inclusion bodies. The bacterial cell cultures were pelleted by centrifugation. Pelleted cells were resuspended in 30 ml lysis buffer (50 mM TRIS HCl pH 8.0, 5 mM EDTA with 10 mM dithiothreitol (DTT)) per 1 L of cell culture. Cell lysis was achieved under high pressure using an Emulsiflex C5 homogenizer, with 0.5% Triton-X added to the sample during lysis. The lysate was then incubated at room temperature with 0.2 mg of DNase and 4 mM MgCl₂ for 30 minutes. The lysate was centrifuged at 15,000 g for 20 minutes and the supernatant discarded. Centrifugation and removal of the supernatant was repeated after resuspension with the following wash buffers; Buffer A (50 mM Tris pH 8.0, 5 mM EDTA, 10 mM DTT, 0.5% v/v Triton-X 100), Buffer A with 2 M NaCl and finally Buffer A without Triton-X 100. The purified inclusion body was pelleted by centrifugation and stored at -20 °C. Inclusion body pellets (from 1 L of bacterial cell culture) were re-suspended in 5 to 10 ml in 100 mM TCEP pH 7.2, then solubilised with the addition of 15 to 30 ml 8 M guanidine hydrochloride, 50 mM Tris-HCl pH 8.0 and 10 mM EDTA. Samples were then incubated at room temperature for 20 minutes, clarified by centrifugation and buffer exchanged into deionised 6 M urea with 20 mM HCl using Sephadex G25 column (Cytiva). The protein concentration was adjusted to ≤ 1 mg/ml by rapid dilution in urea buffer (100 mM TRIS pH 8.0, 1.2 M urea, 1 M PPS, 0.2 mM L-cystine) For refolding of the heterodimeric GDF-15 (HD), equal quantities of denatured H and D forms of GDF-15 were mixed before dilution in

refolding buffer. This resulted in a “heterozygous mix” containing GDF-15 HD, HH and DD as confirmed by mass spectrometry (MS) with an approximate 1:2:1 ratio of HH:HD:DD. Refolded GDF-15 was captured by ion-exchange chromatography using SOURCE 30S column (Cytiva) and fractions containing the disulfide linked dimer polished using reversed phase chromatography using an ACE5 C8-300, size 4.6×250 (HiChrom). Eluted fractions were analysed by non-reducing SDS-PAGE. Fractions with pure GDF-15 dimer were pooled together, with the concentration determined by UV absorption at 280 nM using calculated absorption coefficient. Aliquots of 250 µg were vacuum dried and stored at -80°C. For subsequent assays, the proteins were suspended to 1 mg/ml in 10 mM HCl and diluted to desired concentration in buffer containing bovine serum albumin.

Immunoassays

Roche Elecsys® GDF-15

Samples were analysed using the Roche Elecsys® e411 GDF-15 Cobas electrochemiluminescent immunoassay (Roche Diagnostics, Burgess Hill, UK). In the first incubation, GDF-15 in the sample, the biotinylated monoclonal GDF-15 specific antibody and a second monoclonal GDF-15 specific antibody conjugated to rheuthinium form a sandwich complex. In the second incubation, after addition of streptavidin-coated microparticles, the complex becomes bound to the microparticles via interaction of biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the complex-microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with wash solution (ProCell II M). Application of a voltage to the electrode then induces electrochemiluminescent emission which is measured by a photomultiplier. Results are determined via a calibration curve which is instrument specifically generated by 2-point calibration and a master curve provided via the Cobas link. The limit of detection for the assay was 400 pg/ml, with an upper measurement limit of 20,000 pg/ml. Samples that were initially above the measuring range were diluted in Roche 'Multiassay diluent'. Assays were calibrated and quality

controlled using the manufacturer's reagents. Coefficient of variation was 3.8% for the low control (at 1556 pg/ml) and 3.4% for the high control (at 7804 pg/ml)

R&D Quantikine® ELISA Assay

This is a quantitative sandwich enzyme immunoassay with a monoclonal antibody specific for GDF-15 pre-coated onto a microplate. Standards and samples are pipetted, in duplicate, into the wells and any GDF-15 present is bound by the immobilized antibody. After washing, a horse radish peroxidase (HRP) conjugated polyclonal antibody specific for GDF-15 is added to the wells. Following a wash to remove any unbound conjugate, a substrate solution is added to the wells and colour develops in proportion to the amount of GDF-15 bound in the initial step. The colour development is stopped with acid and the absorbance of the solution is measured on the Perkin Elmer Victor3 plate reader. The assay was controlled using in-house generated controls based on anonymised serum and plasma pools as used for the MSD R&D DuoSet® in-house assay.

The limit of detection of the assay is 17.6 pg/ml with an upper limit of the standard curve of 1500 pg/ml (manufacturer's data). The between batch imprecision is 6.0% at 225 pg/ml, 4.7% at 442 pg/ml, and 5.6% at 900 pg/ml (manufacturer's data).

MesoScale Discovery (MSD) R&D DuoSet® in-house assay

The assay is an in-house microtitre plate-based two-site electrochemiluminescence immunoassay using the MesoScale Discovery assay platform (MSD, Rockville, Maryland, USA). Antibodies and standards were purchased as a DuoSet® (catalogue number DY957) from R&D Systems (BioTechne, Abingdon, UK). Standard-bind MSD microtitre plates were coated overnight with monoclonal anti-GDF-15 capture antibody diluted in PBS. After coating, the plate was washed three times with PBS/Tween using a ThermoFisher automated plate washer and then blocked with MSD Blocker A. After blocking, 40 µl assay diluent plus 10 µl Standards, QCs and undiluted sample were added to the plate in duplicate. After 2 h incubation at room temperature on a plate shaker, the plate was washed

three times with PBS/Tween. Biotinylated polyclonal goat anti-human GDF-15 detection antibody was diluted in MSD Diluent 100 and added to the plate. After 1 h incubation at room temperature on a plate shaker and washing with PBS/Tween, Sulpho-TAG labelled Streptavidin (MSD) diluted in MSD Diluent 100 was added to the plate. The plate was incubated on a plate shaker for a further 30 minutes.

After another wash step, MSD read-buffer was added to all the wells and the plate was immediately read on the MSD s600 plate reader. Luminescence intensities for the standards were used to generate a standard curve using MSD's Workbench software package. The assay was controlled using in-house generated controls based on anonymised serum and plasma pools.

The limit of detection of the assay is 3.0 pg/ml with an upper limit of the standard curve of 32,000 pg/ml (in-house data). The between batch imprecision is 9.8% at 352 pg/ml, 7.8% at 1476 pg/ml, 8.0% at 6593 pg/ml and 6.1% at 12134 pg/ml (in-house data).

GDF-15 Bioassay of Recombinant GDF-15 Protein Constructs

GDF-15 bioactivity assays were performed in HEK293S-SRF-RET/GFRAL cells. This stable cell line was modified to express full length human RET and GFRAL receptors as well as serum response factor-responsive luciferase reporter gene by AstraZeneca. Cells were grown and seeded in T75 flasks in DMEM GlutaMAX (Gibco) supplemented with 10% foetal bovine serum (FBS) (Gibco) and incubated for 30 h at 37°C, with 5% carbon dioxide. Post incubation, media was switched to serum free DMEM and cells were then incubated overnight under the same conditions. The following day, cells were detached using Accutase enzyme and then neutralised in DMEM with 1% FBS. Cells were then pelleted by centrifugation and resuspended in serum free DMEM with an additional 25 mM HEPES pH 7.2 (GDF-15 bioassay media). Cells in suspension were counted using a Cedex automatic cell counter (Roche) and Trypan Blue (Sigma) staining as standard. After counting, cells were then diluted to 500,000 cells/ml in GDF-15 bioassay media before plating in 384-well plates (15 µl/well). After plating, 5 µl of recombinant GDF-15 in GDF-15 bioassay media was then added to the cells at

4x the final concentration. Cells with recombinant protein samples were then incubated for 5 h at 37°C, with 5% carbon dioxide. After 5 h, the plate was then equilibrated to room temperature before the addition of Steady-Glo Luciferase Assay System solution (Promega) at 12µl/well and incubated for a further 20 minutes. The luminescence was measured using an EnVision plate reader (Perkin Elmer) with crosstalk correction applied. CHO derived recombinant Human GDF-15/MIC-1 (PeproTech 120-28C) was used as a positive control. Negative controls of protein sample buffers only were also screened to confirm absence of signalling activity. Triplicates of each dose were performed, and data was analysed in GraphPad 7.0 (Prism).

Regression equations

Passing-Bablok regressions²⁰ were run using the R package mcr (v.1.2.1)²¹ for N = 173 patients to obtain correction equations between the MSD R&D DuoSet® in-house and Roche immunoassays, stratified by genotype.

Results

Recovery of the D variant in synthetic peptides

We synthesised three forms of GDF-15 (HH homodimers, DD homodimers and HD heterodimers, the result of a mixture of HH:HD:DD in ratio 1:2:1). Equal amounts of each dimer were serially diluted and assayed using the Roche Elecsys® and the R&D Quantikine® ELISA and MSD R&D DuoSet® immunoassays (see Methods). Table 1 shows the data for the sample with a theoretical concentration of 667 pg/ml. This is the only concentration which was within the working ranges of all three assays. The full data set is included in the Suppl. Table 1. Recoveries of HH and HD with the Roche Elecsys® assay were very similar with a slight reduction (8-15%) in recovery when assaying the D dimer (Table 1 + Suppl. Table 1). With the Roche Elecsys® assay reported results were proportional to dilution from 2000 to 667 pg/ml. The Roche Elecsys® assay has a lower limit of detection of 400 pg/ml and therefore further dilution were reported as <400 pg/ml as expected (Suppl. Table 1). With the MSD R&D DuoSet® immunoassays, which has a lower limit of detection of 3.0 pg/ml the measurements were also proportionate to the dilutions, the percentage recovery was similar across all

dilutions. However, there was a marked difference in measured levels between the types of dimer (Table 1 and Suppl. Table 1).

The R&D Quantikine® ELISA and MSD R&D DuoSet® immunoassays gave comparable results. Recovery of DD dimers with the both of these assays was approximately 45% of that seen with HH dimers, and between 62 and 78% with the HD dimers (Table 1 and Suppl. Table 1).

Recovery of the D variant in human plasma samples.

We compared the circulating concentrations of GDF-15 as measured by the Roche Elecsys® and MSD R&D DuoSet® immunoassays in plasma samples from 173 participants (126 women, 47 men) from the Leipzig Obesity Biobank whose genotype at rs1058587 in the *GDF-15* gene had previously been established from RNA sequencing data using adipose tissue obtained at surgery¹⁸. We selected samples from 61 HH homozygotes, 59 HD heterozygotes and 53 DD homozygotes.

Fig. 1 shows the results of the Mean +-SEM of plasma GDF-15 in participants with all three genotypes. This was consistent with our findings with the synthetic peptides. The concentrations of GDF-15 reported using MSD R&D DuoSet® immunoassay were ~9% lower in HH, 32% lower in HD and 62% lower in DD than those measured by the Roche Elecsys® assay.

From the data produced using the synthetic peptide it appears that the Roche Elecsys® assay is able to detect the three forms of GDF-15 approximately equally. From this we can then attempt to establish a correction factor that could be used, in situations where genotype is known, to convert MSD R&D DuoSet® immunoassay results to an estimation of the Roche Elecsys® assay for samples from individuals who are homozygous or heterozygous for the D mutation. Figure 2 provides a graphical representation the relationship between GDF-15 levels measured using the two assays in the same individuals. Passing Bablok (PB) regression²⁰ was applied to obtain correction equations as it is more resistant to outliers than simple linear regression. The results of the PB regression (Figure 2) were consistent with the outcomes of the t-tests (Figure 1). Equations 1 and 2 describe the necessary corrections for HD heterozygotes and HH homozygotes respectively, confidence intervals for the

regression parameters are given in Figure 2. The 95% confidence intervals for the slopes do not overlap, consistent with strong evidence against the null hypothesis that the slopes are the same gradient.

Equation 1. GDF-15 Roche Elecsys® estimate[pg/ml] = (GDF-15 R&D [pg/ml]) x 1.62 - 36.52pg/ml

Equation 2. GDF-15 Roche Elecsys® estimate [pg/ml] = (GDF-15 R&D [pg/ml]) x 2.84 - 161.7pg/ml

H and D containing forms of GDF-15 have equivalent bioactivity on the GFRAL-Ret receptor

HEK293S cells stably expressing both components of the GDF-15 Receptor, GFRAL and Ret, and containing a serum response factor responsive luciferase reporter gene were exposed to varying concentrations of synthetic forms of GDF-15 to establish their bioactivity. Both HH and DD homodimers of GDF-15 showed indistinguishable activity in their dose-response characteristics with EC₅₀ values of 0.39 nM (95% CI 0.44-0.45 nM) for HH variant and 0.45 nM (95% CI 0.38-0.52 nM) for DD variant (Figure 3).

Discussion

We have found that the reagents used in one frequently used immunoassay for GDF-15, from R&D Systems, systematically and seriously underestimate circulating concentrations of GDF-15 in people who carry one or two copies of the D allele at position 6 of the mature peptide (position 202 of the pro-peptide). In contrast, the Roche Elecsys® assay appears to be far less affected, though studies with *in vitro* peptides suggest that homozygote DD dimers may be under-recovered by around 10%. As the epitopes targeted by commercial immunoassays are proprietary information, we are not in a position to report whether this difference in assay performance reflects the selection of the antibodies used. However, residue 6 of the mature peptide is in a flexible and accessible region of the GDF-15 molecule and is likely to be a site against which antibodies are readily generated. This common amino acid polymorphism might also affect the accurate measurement of GDF-15 by other types of assay components, such as aptamers²². A substantial proportion of the published literature regarding circulating levels of GDF-15, including work from our own laboratory, has used methodology based

on the R&D antibodies and the conclusions of such studies will need to be re-evaluated on the basis of this new information. In general, the assay appears to perform well within a given individual, so findings that measure levels in research participants before and after any experimental manipulations or serially over time should retain their validity. However, any cross sectional studies comparing individuals will need to be viewed with caution as there is a serious risk that an inadvertent and unrecognised imbalance of genotypes between groups would be a critical source of inaccuracy. Furthermore, clinical trials of GDF-15 antagonism are currently being undertaken in states of cachexia²³ with entry criteria for the trials including elevated concentrations of GDF-15. The GDF-15 concentrations may be significantly underestimated in individuals with the D genotype if a genotype affected assay is used, resulting in the unnecessary exclusion of patients from the trial. Genetic variants in and around the GDF-15 gene, one of which is the rs1058587 encoding the H202D variant are associated with the pregnancy-specific condition HG at genome wide levels of significance²⁴. As GDF-15 administration in animals such as shrews and primates results in vomiting, it might have been expected that the SNPs would affect HG risk through increasing circulating levels. However, studies of circulating levels in relation to genotype have not always been directionally consistent with such an effect. The knowledge that the D variant has such a significant effect on measurement by certain assays formats provides a possible explanation for the puzzling findings reported to date. Similarly, when Karhunen et al¹⁴ performed Mendelian randomisation studies asking whether genetic variants increasing GDF-15 levels were associated with BMI, their surprising conclusion that GDF-15 might actually increase body weight could again be explained by the fact that the assay used to measure GDF-15 used R&D reagents. Although we cannot definitely report that these assay inconsistencies explain inconsistencies in the published epidemiological data, we provide a correction factor which we propose can be usefully employed to re-analyse data from genotyped individuals in such Mendelian randomisation studies. It is very likely that the H202D variant under recovery will also occur using other assay methodologies that have been employed in large-scale proteomic studies²¹. A further level of complexity would be provided if there were differences in bioactivity between the H and D variants. The known structure of the GDF-15-GFRAL complex indicates that position 6 in

296 the mature growth factor is not critically involved in this interaction as the data presented here support
 297 the idea that they are bioequivalent. It is at least theoretically possible that the H and D variants could
 298 act in subtly different ways *in vivo*, such as through differential interaction with components of the
 299 extracellular matrix.

300

301 In conclusion, the genetic variant of GDF-15, present in 15-30% of people worldwide, substantially
 302 affects its measurement by one or more widely used assays with implications for the interpretation of
 303 studies employing such assays.

Figure 1. Circulating levels of GDF-15 measured in genotyped human participants using MSD

R&D DuoSet® and Roche Elecsys® immunoassays

Serum GDF-15 concentrations in genotyped 173 participants of the Leipzig Obesity Biobank measured by MSD R&D DuoSet® immunoassay (RD) against serum GDF-15 measured by the Roche Elecsys® immunoassay (Roche) in the same individuals. Abbreviations: Wild type (HH) n=61, heterozygote (HD) n=59, homozygote (DD) n=53. Data are shown as mean $\pm$ SEM. ** P <0.01, **** P <0.0001.

Figure 2. Serum GDF-15 concentrations in genotyped persons (n = 173) measured by MSD R&D DuoSet® immunoassay plotted against serum GDF-15 measured by Roche Elecsys® immunoassay in the same individual. Passing Bablok regression lines are given, line colours represent the genotype of the respective person at rs1058587 and dotted lines the 95% CIs. Numerical values for intercepts and slopes with 95% CIs in square brackets are given. The solid black line denotes the diagonal. Abbreviations: HH - homozygote for wild type, HD – heterozygote, DD – homozygous mutation.

Figure 3. Bioactivity of H and D containing GDF-15 dimers on GFRAL-Ret signalling

Bioactivity of HH and DD variant mature GDF-15 in HEK293S-SRF-RET/GFRAL cells with luciferase reporter under serum responsive factor control. CHO derived recombinant human GDF-15/MIC-1 (PeptoTech) was used as a positive control.

340 **Table 1. Percentage recovery of synthetic GDF-15 dimers HH, HD and DD using three immunoassays.**

GDF-15 Dimer type	Theoretical (pg/ml)	Roche Elecsys® assay			MSD R&D DuoSet® in-house assay			R&D Quantikine® ELISA		
		Measured (pg/ml)	Recovery to theoretical (%)	Recovery to HH (%)	Measured (pg/ml)	Recovery to theoretical (%)	Recovery to HH (%)	Measured (pg/ml)	Recovery to theoretical (%)	Recovery to HH (%)
HH	667	882	132	n/a	1027	1549	n/a	1154	173	n/a
HD	667	877	131	1005	795	119	78	716	107	62
DD	667	774	116	88	446	67	44	523	78.	45

341

342 Abbreviations: HH - homozygote for wild type, HD – heterozygote, DD – homozygous mutation, n/a not applicable.

343

References:

1. Tsai, V.W., Lin, S., Brown, D.A., Salis, A. & Breit, S.N. Anorexia-cachexia and obesity treatment may be two sides of the same coin: role of the TGF- β superfamily cytokine MIC-1/GDF15. *International journal of obesity* (2005) **40**, 193-197 (2016).
2. Sekine, I., Segawa, Y., Kubota, K. & Saeki, T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. *Cancer science* **104**, 711-717 (2013).
3. Birkeland, E., *et al.* Norwegian PUQE (Pregnancy-Unique Quantification of Emesis and nausea) identifies patients with hyperemesis gravidarum and poor nutritional intake: a prospective cohort validation study. *PloS one* **10**, e0119962 (2015).
4. Montero, R., *et al.* GDF-15 Is Elevated in Children with Mitochondrial Diseases and Is Induced by Mitochondrial Dysfunction. *PloS one* **11**, e0148709 (2016).
5. Ji, X., *et al.* Growth Differentiation Factor 15 Is a Novel Diagnostic Biomarker of Mitochondrial Diseases. *Molecular neurobiology* **54**, 8110-8116 (2017).
6. Yatsuga, S., *et al.* Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. *Annals of neurology* **78**, 814-823 (2015).
7. Corre, J., Hébraud, B. & Bourin, P. Concise review: growth differentiation factor 15 in pathology: a clinical role? *Stem cells translational medicine* **2**, 946-952 (2013).
8. Kempf, T., *et al.* Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. *Journal of the American College of Cardiology* **50**, 1054-1060 (2007).
9. Yang, L., *et al.* GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. *Nature medicine* **23**, 1158-1166 (2017).
10. Mullican, S.E., *et al.* GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. *Nature medicine* **23**, 1150-1157 (2017).
11. Emmerson, P.J., *et al.* The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. *Nature medicine* **23**, 1215-1219 (2017).
12. Hsu, J.Y., *et al.* Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. *Nature* **550**, 255-259 (2017).
13. Macia, L., *et al.* Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. *PloS one* **7**, e34868 (2012).
14. Karhunen, V., Larsson, S.C. & Gill, D. Genetically proxied growth-differentiation factor 15 levels and body mass index. *British journal of clinical pharmacology* **87**, 4036-4039 (2021).
15. Howe, K.L., *et al.* Ensembl 2021. *Nucleic Acids Res* **49**, D884-d891 (2021).
16. Brown, D.A., *et al.* Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. *BioTechniques* **33**, 118-120, 122, 124 passim (2002).
17. Auton, A., *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).
18. Langhardt, J., *et al.* Effects of Weight Loss on Glutathione Peroxidase 3 Serum Concentrations and Adipose Tissue Expression in Human Obesity. *Obesity facts* **11**, 475-490 (2018).
19. Klöting, N., *et al.* Insulin-sensitive obesity. *American journal of physiology. Endocrinology and metabolism* **299**, E506-515 (2010).
20. Passing, H. & Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. *Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie* **21**, 709-720 (1983).
21. Manuilova, E., Schuetzenmeister, A. & Model, F. MCR: method comparison regression. *R package version* **1**(2014).
22. Pietzner, M., *et al.* Mapping the proteo-genomic convergence of human diseases. *Science (New York, N.Y.)*, eabj1541 (2021).

- 395 23. Suzuki, H., *et al.* Clinical and Tumor Characteristics of Patients with High Serum Levels of
396 Growth Differentiation Factor 15 in Advanced Pancreatic Cancer. *Cancers* **13**(2021).
- 397 24. Fejzo, M.S., *et al.* Placenta and appetite genes GDF15 and IGFBP7 are associated with
398 hyperemesis gravidarum. *Nature communications* **9**, 1178 (2018).
- 399